0001372514-23-000034.txt : 20230307
0001372514-23-000034.hdr.sgml : 20230307
20230307201450
ACCESSION NUMBER: 0001372514-23-000034
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230303
FILED AS OF DATE: 20230307
DATE AS OF CHANGE: 20230307
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Daniels Eric Joseph
CENTRAL INDEX KEY: 0001892943
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36672
FILM NUMBER: 23714566
MAIL ADDRESS:
STREET 1: C/O EYEGATE PHARMACEUTICALS INC.
STREET 2: 271 WAVERLY OAKS RD., STE 108
CITY: WALTHAM
STATE: MA
ZIP: 02452
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: KIORA PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001372514
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 332 ENCINITAS BOULEVARD
STREET 2: SUITE 102
CITY: ENCINITAS
STATE: CA
ZIP: 92024
BUSINESS PHONE: 781-788-8869
MAIL ADDRESS:
STREET 1: 332 ENCINITAS BOULEVARD
STREET 2: SUITE 102
CITY: ENCINITAS
STATE: CA
ZIP: 92024
FORMER COMPANY:
FORMER CONFORMED NAME: EYEGATE PHARMACEUTICALS INC
DATE OF NAME CHANGE: 20060811
4
1
wf-form4_167823807843002.xml
FORM 4
X0306
4
2023-03-03
0
0001372514
KIORA PHARMACEUTICALS INC
KPRX
0001892943
Daniels Eric Joseph
332 ENCINITAS BLVD., SUITE 102
ENCINITAS
CA
92024
0
1
0
0
Chief Development Officer
Common Stock
2023-03-03
4
A
0
15600
0
A
25838
D
Stock Option (right to buy)
3.83
2023-03-03
4
A
0
10400
0
A
2033-03-03
Common Stock
10400.0
10400
D
Grant of restricted stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan (the "Plan"). The restrictions will vest as to one-third (1/3) of the shares on each of March 3, 2024, March 3, 2025 and March 3, 2026, subject to the reporting person's continuous service through each such vesting date.
The reporting person received an option to purchase Common Stock from the Issuer pursuant to the Plan. The option will become exercisable as to one-third (1/3) of the shares underlying the Option on March 3, 2024, and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years, subject to the reporting person's continuous service through each such vesting date.
/s/ Robert A. Petitt, Attorney-in-Fact
2023-03-08